627 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study http://www.zacks.com/stock/news/509890/lillys-ret-inhibitor-shrinks-tumors-in-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509890 Sep 09, 2019 - Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.
Novartis Announces Positive Long-Term Data on Migraine Drug http://www.zacks.com/stock/news/509529/novartis-announces-positive-long-term-data-on-migraine-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509529 Sep 09, 2019 - Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
4 Biotech Stocks With Big Catalysts in September https://www.fool.com/investing/2019/09/05/biotech-stocks-with-big-catalysts-in-september.aspx?source=iedfolrf0000001 Sep 05, 2019 - Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC http://www.zacks.com/stock/news/503575/astrazenecas-tagrisso-gets-nod-in-china-for-first-line-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503575 Sep 05, 2019 - AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? https://www.fool.com/investing/2019/09/05/is-the-fda-out-to-get-this-29-billion-diabetes-dru.aspx?source=iedfolrf0000001 Sep 05, 2019 - It’s rejected a pair of drugs in the last six months.
J&J's Stelara Gets Approval in EU for Ulcerative Colitis http://www.zacks.com/stock/news/503348/jjs-stelara-gets-approval-in-eu-for-ulcerative-colitis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503348 Sep 05, 2019 - Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).
Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M http://www.zacks.com/stock/news/501399/vertex-vrtx-inks-all-cash-deal-to-acquire-semma-for-%24950m?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-501399 Sep 04, 2019 - Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.
Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs http://www.zacks.com/stock/news/495944/pharma-stock-roundup-jnjs-opioid-lawsuit-regulatory-nod-for-lly-bmy-rhhby-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-495944 Aug 30, 2019 - Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.
Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More http://www.zacks.com/stock/news/453588/busy-morning-for-investors-trade-data-earnings-for-pfe-mrk-cop-more?cid=CS-ZC-FT-ahead_of_wall_street-453588 Jul 30, 2019 - Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.
Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients http://www.zacks.com/stock/news/431041/novo-nordisks-victoza-gets-fda-nod-for-pediatric-patients?cid=CS-ZC-FT-431041 Jun 18, 2019 - Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.

Pages: 123456789...63

<<<Page 4>